A lthough ovarian cancer is uncommon, it is the fifthleading cause of cancer mortality among US women. Based on data from 2010-2014, the estimated annual incidence rate was 11.4 per 100 000 and the mortality rate was 7.4 per 100 000, with a projected 14 080 deaths from ovarian cancer in 2017. 1, 2 More than 60% of cases are diagnosed after the cancer has metastasized. 2 Screening trials have shown no effect on mortality and have documented harms; positive test results from screening asymptomatic women often reveal benign pelvic conditions or normal ovaries on surgical investigation, and cancer cases are often missed with screening. [3] [4] [5] In 2012, the US Preventive Services Task Force (USPSTF) concluded that there was at least moderate certainty that the harms of screening for ovarian cancer outweighed the benefits, and it issuedaDgraderecommendation against screening in asymptomatic women. The current review was undertaken to update the evidence on population-based screening for ovarian cancer for an updated recommendation on this topic.
Methods

Scope of Review
This evidence review addresses 2 key questions (KQs) related to benefits and harms of screening for ovarian cancer in asymptomatic women ( Figure 1 ). Methodological details regarding search strategies, detailed study inclusion criteria, quality assessment, excluded studies, and description of data analyses, as well as detailed results, are publicly available in the full evidence report at https://www.uspreventiveservicestaskforce.org/Page /Document/UpdateSummaryFinal/ovarian-cancer-screening1.
Data Sources and Searches
A search of MEDLINE, PubMed publisher-supplied records, and the Cochrane Collaboration Registry of Controlled Trials for studies published between January 2003 and January 2017 built on a previous search conducted on behalf of the USPSTF (eMethods in the Supplement). 7 Studies also were identified from previous reviews, meta-analyses, and reference lists. 5,7-10 ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform were searched for ongoing trials. Since January 2017, ongoing surveillance to identify new studies that might affect the review conclusions or interpretation of the evidence was conducted using article alerts and targeted searches of journals with high impact factors. The last surveillance, conducted on November 22, 2017, identified an additional publication reporting secondary analyses of one of the included trials.
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Study Selection
Two reviewers independently reviewed titles, abstracts, and full article text to identify studies meeting predetermined review inclusion and exclusion criteria (eTable 1 in the Supplement). Discrepancies were resolved by discussion. Randomized clinical trials of screening compared with no screening or usual care comparisons that enrolled asymptomatic, average-risk women 45 years and older were included. Trials focused on screening explicitly among high-risk populations (eg, BRCA mutation carriers, individuals with first-degree relatives with ovarian cancer), and those addressing only the accuracy of screening or cancer detection rates without reporting morbidity, mortality, or quality-of-life data, were not included.
Data Extraction and Quality Assessment
Two reviewers independently assessed the methodological quality of all eligible studies, using criteria outlined by the USPSTF (eTable 2 in the Supplement), 12 and resolved discordant ratings through discussion. Good-quality randomized clinical trials had adequate randomization procedures and allocation concealment, blinded outcome assessment, reliable outcome measures, similar baseline characteristics between groups, and low attrition. Good-quality trials also used intention-to-screen analysis and reported diagnostic criteria for outcome ascertainment. Fairquality studies were assessed as not meeting all of the quality criteria but did not have critical limitations that could invalidate study findings. Trials were rated poor quality if attrition was greater than 40% or differed between groups by 20% or if there were other study design or implementation flaws that would seriously undermine internal validity.
Data Synthesis and Analysis
One reviewer abstracted data into standard evidence tables, and the second reviewer checked them for accuracy. Descriptive synthesis was conducted, with results reported and discussed by screening strategy. Meta-analytic pooling of results was not conducted because of the small number of studies and heterogeneity of interventions. Some outcomes were calculated from raw data reported in study publications to adhere to task force priorities or to facilitate comparability across trials and thus may differ from the findings highlighted in the main results of the original publications. were abstracted or calculated using this definition when possible, even if it was not the primary trial outcome reported. Screening false-positive rates were calculated as the percentage of women not diagnosed with ovarian cancer who experienced a positive screening result that led to follow-up testing. False-positive surgery rates were calculated as the percentage of women without an ovarian cancer diagnosis who were referred to surgery for investigation of suspected ovarian cancer based on positive screening and follow-up test results. Because each definition provides different insights, false-positive rates based on both definitions were calculated for all included studies that reported the pertinent data. When multiple statistical tests were presented in publications, the prespecified statistical analyses from trial protocols were prioritized, as were complete intention-to-screen analyses and clinically meaningful mortality outcomes for ovarian cancer as defined above. 18 The strength of the overall body of evidence for each key question was graded as high, moderate, low, or insufficient based on established methods 19 and addressed the consistency, precision, and limitations of the body of evidence related to each outcome. For more details on review methods, see the full report.
Results
A total of 1381 titles and abstracts and 74 articles were reviewed. After full text review and critical appraisal, 4 trials (N = 293 587) in 17 publications were included ( Figure 2 ). 20-36 Three trials reported health outcomes (KQ1), and all 4 trials reported potential harms of screening (KQ2) ( and the fair-quality QUEST 29 trial (n = 549). The largest (n = 202 546), most recent trial is UKCTOCS, which enrolled participants through 13 National Health Service centers in England, Wales, and Northern Ireland. The smaller (n = 21 935) UK Pilot trial, conducted by the same research group in preparation for UKCTOCS, 33 recruited women who had participated in a previous ovarian cancer screening study. 32 The PLCO trial (n = 68 557) was conducted at 10 clinical screening centers in the United States.
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Figure 1. Analytic Framework and Key Questions
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Key questions
Does screening for ovarian cancer in asymptomatic women using single tests or combined algorithms (such as, but not limited to, cancer antigen 125 [CA-125] and ultrasound) reduce all-cause or disease-specific morbidity and mortality? e Exclusion based on colorectal cancer screening began 1995. Trial initially excluded women with previous oophorectomy (dropped in 1996) and current tamoxifen use (dropped in 1999).
f High risk of ovarian cancer: reported family history predicted at least a 10% probability of a germline mutation in the BRCA1 or BRCA2 genes or Amsterdam criteria for hereditary nonpolyposis colorectal cancer syndrome. ; therefore, those results are limited to primary cancer of the ovary and fallopian tubes.
Benefits of Screening
Key Question 1. Does screening for ovarian cancer in asymptomatic women using single tests or combined algorithms (such as, but not limited to, cancer antigen 125 [CA-125] and ultrasound) reduce all-cause or disease-specific morbidity and mortality?
Three good-quality trials (n = 293 038) met the inclusion criteria for KQ1 (Table 1) .
In the UKCTOCS and UK Pilot trials, the racial or ethnic composition of the study population was more than 95% white, 31,33 and in the PLCO trial 88% of women were white and non-Hispanic. In the UKCTOCS trial, women considered at "high risk" of familial ovarian cancer were explicitly excluded, but 1.6% of women reported maternal history of ovarian cancer and 6.4% a maternal history of breast cancer. In the PLCO trial, 21 17% of women reported any family history of breast or ovarian cancer.
All 3 trials evaluated annual screening for ovarian cancer with CA-125 testing, transvaginal ultrasound, or both ( Table 2 ). The UKCTOCS trial had 2 intervention groups and a no-screening control group (randomized 1:1:2, respectively). Women were originally randomized to receive annual screening for 6 years, but the protocol was modified to extend screening. Women randomized to the intervention group received 7 to 11 rounds of annual screening using CA-125 serum testing (with triage and follow-up determined by the risk of ovarian cancer algorithm [ROCA]) 39,40 or yearly transvaginal ultrasound testing with a median of 11.1 years of follow-up. 31 The CA-125 ROCA screening group was described as multimodal screening in the UKCTOCS trial publications and included a standard protocol for all follow-up testing. The ROCA is more complex than singlecutpoint CA-125 testing because it incorporates changes in CA-125 level over time for individual women. The UK Pilot 33 trial compared 3 rounds of annual CA-125 screening tests having a fixed cutpoint (Ն30 U/mL) with no screening over 8 years of follow-up.
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Women in the screening intervention group of the PLCO trial received both CA-125 testing with a fixed cutpoint (Ն35 U/mL) and e Extended from original protocol of 6 screening rounds based on interim analysis.
f Annual bimanual clinical examination of the ovaries discontinued in 1998 because no cases were identified solely with this screening test.
g During the first screen, ultrasonography was performed transabdominally.
Transvaginal ultrasonography was used in the second and third screens.
h All women in this trial (including the control group) had undergone a previous round of screening approximately 10 years prior. ultrasonography. 20, 21 Bimanual palpation of the ovaries was also included in the screening intervention during the first 4 years of study enrollment but was discontinued because no cancers were identified only on the basis of this examination. 41 A protocol modification also extended screening to a maximum of 6 screening rounds (4 with CA-125 and transvaginal ultrasound, 2 with CA-125 alone), with a median of 12.4 years of follow-up. Overall, screening adherence was high, follow-up rates were variable but balanced, and contamination across groups was minimal. Ovarian cancer was diagnosed in 0.6% of women (388 cases) in the PLCO trial, 0.7% of women (1323 cases) in the UKCTOCS trial, and 0.2% of women (36 cases) in the UK Pilot trial. Across all trials, incidence did not differ by study group.
CA-125 Screening
In the UKCTOCS trial, ovarian cancer mortality (including fallopian tube and peritoneal cancer) with the CA-125 ROCA screening program was similar in the intervention and control groups (0.32% for intervention vs 0.35% for control), and in survival analysis there were 2.9 ovarian cancer deaths per 10 000 person-years in the intervention group and 3.3 ovarian cancer deaths per 10 000 person-years in the control group. This difference was not statistically significant (hazard ratio, 0.89 [95% CI, 0.74-1.08]) 31 (Table 3 ). In the smaller UK Pilot 33 trial (n = 21 935), there were 9 ovarian cancer (peritoneal cancer not reported) deaths in the intervention group (0.08%) and 18 in the no-screening comparison group (0.16%); the difference was not statistically significant (relative risk , 0.50 [95% CI, 0.22-1.11]). A statistically significant difference in survival between women with index cancers in the intervention and control groups was observed when computed from the date of randomization (median, 72.9 months for intervention group vs 41.8 months for control group; P = .01). This finding was based on a small number of events, and survival in the control group was noted by the study authors as being "unexpectedly poor," with only 2 of 20 women who developed an index cancer surviving.
Transvaginal Ultrasound Screening
In the UKCTOCS trial, 31 transvaginal ultrasound screening did not reduce ovarian cancer mortality compared with no screening (0.32% for intervention group vs 0.35% for control group) ( e The false-positive rate from the baseline screening round was 9.0% (4513/50 031). False-positives from baseline screening could not be combined with rates from screening rounds 2 to 11 because of differences in denominators. Cumulative data reported for women screened in rounds 2 to 11 were based on a denominator of women who continued screening after the first round.
f Includes bruising (13), pain (8), hematoma (3), fainting (1), cystitis/infection (1), other (4). A study of the psychological morbidity associated with ovarian cancer screening was undertaken within the UKCTOCS trial 25 using an annual survey of a random sample of women drawn at baseline from each trial group (n = 1339) and surveys of all women in the screening groups who were recalled for follow-up testing (eTable 3 in the Supplement). No statistically significant differences in anxiety or risk of psychological morbidity were observed between the control and intervention groups in the random sample. In the analysis of women with recall screening events, there was a small, though statistically significant, effect of repeat screening on anxiety (P < .01) and an increased risk of psychological morbidity among women recalled for higher-level screening (12-Item General Health Questionnaire score Ն4, adjusted odds ratio, 1.28 [95% CI, 1.18-1.39]). 25 The small QUEST trial (n = 549) similarly found a higher level of cancer worry among women who had experienced any abnormal test results.
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Discussion A summary of the evidence for this review is reported in Table 5 .
Since the previous review of this topic for the USPSTF, ovarian cancer mortality findings were published from the largest trial to date, the UKCTOCS trial. Evidence from 2 large trials in the United States and the United Kingdom among asymptomatic average-risk women does not indicate that screening reduces ovarian cancer mortality. The smaller UK Pilot trial was designed to assess feasibility and performance of screening and was not powered to test mortality differences. The UKCTOCS trial assessed a proprietary screening and follow-up intervention that led to fewer women without cancer undergoing surgery and experiencing complications in comparison to the PLCO trial. Nevertheless, in both trials the operations and complications occurred in the absence of a mortality benefit for the screened population. Trial results from the complete intention-to-treat analysis of ovarian cancer mortality defined according to clinically relevant international standards are applicable to the implementation of a screening program and its cumulative effects. 42, 43 Both of the large trials also provided additional analyses to explore effects and generate hypotheses. Additional published analyses of UKCTOCS data suggested a mortality benefit for CA-125 ROCA screening when peritoneal cancer cases were excluded and a statistical test assigning greater weight to later years of the trial was used. In the UKCTOCS trial, a greater proportion of cancers was identified as peritoneal in the CA-125 ROCA group than in the no screening group (5% vs 2%). Excluding cases with high mortality could heighten differences between the CA-125 ROCA and control groups. Excluding peritoneal cancers and relying on protocol-specified statistical testing, there was not a statistical difference in ovarian cancer mortality. Another planned analysis of UKCTOCS aimed to remove certain prevalent ovarian cancer cases selected based on stored CA-125 test results, data imputation, and statistical modeling. Results of that analysis are potentially hypothesis generating but are more subject to bias than the full intention-to-treat analysis of the trial. Additional analyses of PLCO trial data include a recently published analysis adding up to 6 years of posttrial mortality data (mean, 2.3 years) to the PLCO trial and did not find evidence of a longerterm benefit of screening.
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The high mortality and low 5-year survival among all women diagnosed with ovarian cancer may be attributable to continued challenges detecting the disease at an early stage. 44 In PLCO, there was no statistically significant difference in the proportion of cases identified at the localized stage in the intervention vs usual care group (15% vs 10%, respectively; P = .08). Comparisons by stage and group also were not statistically different when comparing localized and regional cancer cases with more advanced cancers. In the UKCTOCS trial, a greater proportion of cases was identified at the localized stage (stage I) with CA-125 ROCA screening (36%) and transvaginal ultrasound screening (31%) compared with the control group (23%) (P < .005). The overall differences by group and stage were also statistically significant when comparing localized and regional cancers (stages I and II) with more advanced cancers (stages III and IV). 31 Although no overall mortality benefit was associated with these observed stage shifts, these comparisons are relevant because of clinical differences in treatment strategies between stage I and higher-stage ovarian cancer (ie, need for adjuvant radiation therapy); treatment outcomes in the UKCTOCS trial have not yet been published. Cancer type is also important, as it defines 2 broad categories of epithelial ovarian cancer with shared clinical and histological features that represent distinct models of epithelial ovarian carcinogenesis. 45 Type I tumors include low-grade, generally indolent tumors, which are often associated with somatic mutations in a number of genes (eg, KRAS, BRAF, ERBB2) and develop from benign extraovarian lesions implanted on the ovary. 16 Although no significant difference in mortality was found in the more recent UKCTOCS trial, advances were made in reducing the number of women without cancer who underwent diagnostic surgery, compared with earlier trials. The UKCTOCS trial took a more nuanced and regimented approach to CA-125 testing and triage by using an algorithm that incorporates CA-125-level trajectories to assign 3 levels of risk, with protocol-driven surveillance and triage testing for follow-up. Accordingly, surgery rates were lower in the CA-125 ROCA group than in the transvaginal ultrasound-only group of the trial and also compared with screening in the PLCO trial (1% vs 3%).
In addition, surgical complication rates were lower in the UKCTOCS trial than in the PLCO trial. Fifteen percent of women without cancer who underwent surgery experienced a major complication in the PLCO trial, compared with just more than 3% in the UKCTOCS trial. Differences in study setting could partly account for this, because diagnostic testing in the PLCO trial was conducted through referrals to women's routine sources of care and not necessarily specialized tertiary care settings. In contrast, in the United Kingdom, all women referred for diagnostic testing were seen at National Health Service tertiary care surgical centers. Regardless of the complication rates, however, high rates of surgery and removal of a single ovary or both ovaries in the absence of disease occurred in both trials.
Evidence from a recent systematic review reported on health effects associated with bilateral salpingo-oophorectomy at the time of benign hysterectomy. 49 Removal of the ovaries, in the absence medical indication, may affect cardiovascular health, all-cause mortality, mental health, and sexual function. In addition to potential surgical complications that could accompany the removal of women's ovaries, fallopian tubes, or both at the time of a surgical investigation for a false-positive screening test, harms from ovary removal without indication cannot be ruled out. 
Limitations
This review has limitations related to the types of evidence considered. Observational evidence was not included, owing to the availability of adequately powered trials that can estimate the mortality reduction from screening relative to an unscreened group. These trial comparisons summarize the net effect of screening, detection, and treatment 6 and are considered by the USPSTF to be the highest level of evidence for screening recommendations. 6 Given the low incidence of ovarian cancer, very large trials are necessary to determine whether benefits of a screening program outweigh harms, which for ovarian cancer include surgery and ovarian removal. The strict inclusion and exclusion criteria related to study design and outcome reporting excluded evidence from 2 large studies: the Shizuoka Cohort Study of Ovarian Cancer Screening (SCSOCS) Randomized trial evidence can have limitations in terms of generalizability and applicability to usual care. Nearly all trial participants in the UKCTOCS trial were white women, and just 12% of women enrolled in the PLCO trial identified as of minority race or ethnicity. The PLCO trial is potentially more applicable to a US setting than the UKCTOCS trial, given differences in health care systems and the referral to usual care for treatment in the PLCO trial. The low surgical complication rates from surgery seen in the UKCTOCS trial, for example, may have been attributable to the receipt of care in tertiary care centers. It is also possible that screening tests offered through a trial might would be more accurate than screening in routine care or that surgical investigations might be more common in the absence of trial protocols. In addition, the definition of false-positive surgery may underestimate surgical harms, given the absence of a mortality benefit from ovarian cancer screening. Surgery undertaken on the basis of screening, even when cancer was diagnosed, did not lead to significantly reduced mortality from ovarian cancer.
Conclusions
In randomized trials conducted among average-risk, asymptomatic women, ovarian cancer mortality did not differ between screened women and those with no screening or in usual care. Screening harms included surgery (with major surgical complications) in women found to not have cancer. Further research is needed to identify effective approaches for reducing ovarian cancer incidence and mortality. 
